Barclays lowered the firm’s price target on Editas Medicine (EDIT) to $3 from $5 and keeps an Equal Weight rating on the shares. The company’s restructuring update included reni-cel discontinuation with no commercial partner identified and a workforce reduction including the chief medical officer, the analyst tells investors in a research note. The firm says the reprioritizing resets Editas Medicine’s development phase by years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine downgraded to Hold from Buy at Truist
- Editas Medicine downgraded to Hold from Buy at Stifel
- Editas Medicine Shifts Focus to In Vivo Gene Editing
- Editas to reduce workforce by 65%, announces departure of CMO Baisong Mei
- Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo